In trading on Monday, shares of Cassava Sciences Inc (Symbol: SAVA) touched a new 52-week low of $16.41/share. That's a $29.88 share price drop, or -64.55% decline from the 52-week high of $46.29 set ...
SAVA has a new potential indication for simufilam, the treatment of seizures related to tuberous sclerosis complex, although the company is not yet running a clinical trial here. SAVA isn't done with ...
NEW YORK, Jan. 9, 2025 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of Cassava Sciences, Inc. (NASDAQ: SAVA). Shareholders who purchased shares of SAVA during the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback